- Home
- EBC vs WGS Comparison
EBC vs WGS Comparison
Compare EBC & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EBC | WGS |
|---|---|---|
| Founded | 1818 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.6B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | EBC | WGS |
|---|---|---|
| Price | $21.29 | $84.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $22.13 | ★ $138.13 |
| AVG Volume (30 Days) | ★ 2.3M | 821.2K |
| Earning Date | 01-22-2026 | 02-23-2026 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | 0.07 |
| Revenue | ★ $696,700,000.00 | $402,190,000.00 |
| Revenue This Year | $57.89 | $41.17 |
| Revenue Next Year | $6.00 | $23.94 |
| P/E Ratio | ★ $50.69 | $1,160.61 |
| Revenue Growth | 4.90 | ★ 50.50 |
| 52 Week Low | $13.51 | $55.17 |
| 52 Week High | $22.58 | $170.87 |
Technical Indicators
Market Signals| Indicator | EBC | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 66.12 | 24.59 |
| Support Level | $19.90 | $82.09 |
| Resistance Level | $22.58 | $101.94 |
| Average True Range (ATR) | 0.64 | 6.92 |
| MACD | 0.16 | -0.69 |
| Stochastic Oscillator | 65.73 | 6.74 |
Price Performance
Historical ComparisonAbout EBC Eastern Bankshares Inc.
Eastern Bankshares Inc is a commercial bank that caters its products and services to retail, commercial, and small business customers. Its diversified products and services include lending, deposit, wealth management, and insurance products. The company has one operating segment; Banking business which offers a range of banking lending, savings, and small business offerings, and its wealth management and trust operations.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.